Adaptimmune Therapeutics Salute del bilancio
Salute finanziaria criteri di controllo 4/6
Adaptimmune Therapeutics ha un patrimonio netto totale di $80.0M e un debito totale di $49.9M, che porta il suo rapporto debito/patrimonio netto a 62.3%. Le sue attività totali e le sue passività totali sono rispettivamente $317.4M e $237.4M.
Informazioni chiave
62.3%
Rapporto debito/patrimonio netto
US$49.87m
Debito
| Indice di copertura degli interessi | n/a |
| Contanti | US$186.09m |
| Patrimonio netto | US$79.99m |
| Totale passività | US$237.45m |
| Totale attività | US$317.44m |
Aggiornamenti recenti sulla salute finanziaria
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20
We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Recent updates
Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding
Nov 15The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%
Sep 26Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
Sep 12Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Jul 03Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Apr 26Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06Circling Back On Adaptimmune Therapeutics
Dec 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
Sep 29We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Aug 14Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( $244.2M ) di ADAP superano le sue passività a breve termine ( $63.5M ).
Passività a lungo termine: Le attività a breve termine di ADAP ( $244.2M ) superano le sue passività a lungo termine ( $174.0M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: ADAP ha più liquidità del suo debito totale.
Riduzione del debito: Il rapporto debito/patrimonio netto di ADAP è aumentato da 0% a 62.3% negli ultimi 5 anni.
Bilancio
Analisi della pista di contanti
Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: ADAP ha una cash runway sufficiente per più di 3 anni in base al suo attuale free cash flow.
Previsione Cash Runway: Dati insufficienti per determinare se ADAP ha una sufficiente pista di cassa se il suo flusso di cassa libero continua a crescere o a ridursi in base ai tassi storici.